<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">FEBS Lett</journal-id>
      <journal-title-group>
        <journal-title>Febs Letters</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0014-5793</issn>
      <issn pub-type="epub">1873-3468</issn>
      <publisher>
        <publisher-name>Elsevier Science B.V</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3018572</article-id>
      <article-id pub-id-type="pmid">21094158</article-id>
      <article-id pub-id-type="publisher-id">FEBS34398</article-id>
      <article-id pub-id-type="doi">10.1016/j.febslet.2010.11.024</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Synthetic lethality: General principles, utility and detection using genetic screens in human cells</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Nijman</surname>
            <given-names>Sebastian M.B.</given-names>
          </name>
          <email>snijman@cemm.oeaw.ac.at</email>
          <xref rid="cor1" ref-type="corresp">⁎</xref>
        </contrib>
      </contrib-group>
      <aff>Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM), 1090 Vienna, Austria</aff>
      <author-notes>
        <corresp id="cor1"><label>⁎</label>Fax: +43 1 40160 970 000. <email>snijman@cemm.oeaw.ac.at</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>03</day>
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <day>03</day>
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <volume>585</volume>
      <issue>1</issue>
      <fpage>1</fpage>
      <lpage>6</lpage>
      <history>
        <date date-type="received">
          <day>3</day>
          <month>11</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>10</day>
          <month>11</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2011 Elsevier B.V.</copyright-statement>
        <copyright-year>2010</copyright-year>
        <copyright-holder>Federation of European Biochemical Societies</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Synthetic lethality occurs when the simultaneous perturbation of two genes results in cellular or organismal death. Synthetic lethality also occurs between genes and small molecules, and can be used to elucidate the mechanism of action of drugs. This area has recently attracted attention because of the prospect of a new generation of anti-cancer drugs. Based on studies ranging from yeast to human cells, this review provides an overview of the general principles that underlie synthetic lethality and relates them to its utility for identifying gene function, drug action and cancer therapy. It also identifies the latest strategies for the large-scale mapping of synthetic lethalities in human cells which bring us closer to the generation of comprehensive human genetic interaction maps.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Synthetic lethality</kwd>
        <kwd>Genetic screens</kwd>
        <kwd>Cancer</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="s0005">
      <label>1</label>
      <title>Introduction</title>
      <p>Synthetic lethality was first described by the American geneticist Calvin Bridges in the early 20th century <xref rid="b0320" ref-type="bibr">[1]</xref>. He noted that when crossing fruit flies (<italic>Drosophila melanogaster</italic>), certain non-allelic genes were lethal only in combination even though the homozygous parents were perfectly viable. The term “synthetic lethality” was coined some 20 years later by his colleague Theodore Dobzhansky who observed the same phenomenon in <italic>Drosophila pseudoobscura</italic> <xref rid="b0325" ref-type="bibr">[2]</xref>. Indeed, <italic>synthetic</italic> is used here for its ancient Greek meaning: the combination of two entities to form something new.</p>
      <p>Synthetic lethality is thus defined as a type of genetic interaction where the co-occurrence of two genetic events results in organismal or cellular death (<xref rid="f0005" ref-type="fig">Fig. 1</xref>) <xref rid="b0005 b0315" ref-type="bibr">[3,4]</xref>. Similarly, genetic combinations that yield a non-lethal growth impairment are called <italic>synthetic sick</italic> but are usually grouped together with synthetic lethal interactions, as is done in this review. Although best known in the context of loss-of-function mutants, combinations of other types of perturbations can also result in synthetic lethality, including overexpression of genes, the action of a chemical compound or environmental change <xref rid="b0015 b0020 b0025 b0030" ref-type="bibr">[5–8]</xref>.</p>
      <p>Geneticists have been interested in synthetic lethal interactions because they reveal information about the functional relationships between genes and are relatively easy to score in genetic screens <xref rid="b0035" ref-type="bibr">[9]</xref>. In addition, as many basic cellular processes are ultimately required for viability, synthetic lethality screens can be used to study a wide range of processes. In recent years, synthetic lethality has attracted attention from cancer biologists as it provides a new angle for therapy and may explain the sensitivity of cancer cells to certain drugs <xref rid="b0025 b0040" ref-type="bibr">[7,10]</xref>. This review intends to provide the conceptual framework and utilities of synthetic lethality and highlights the main strategies to identify them in human cells using functional genetics.</p>
    </sec>
    <sec id="s0010">
      <label>2</label>
      <title>The principles underlying synthetic lethality involve robustness and buffering</title>
      <p>Synthetic lethal genetic interactions exist because of the mechanisms employed by cells and organisms to maintain homeostasis in the face of diverse genetic and environmental challenges <xref rid="b0315 b0045" ref-type="bibr">[4,11]</xref>. This robustness of cells and organisms is thought to play a critical role in evolution, developmental canalization (i.e., the ability to produce the same phenotype regardless of genotype) and multifactorial diseases such as cancer <xref rid="b0050 b0055" ref-type="bibr">[12,13]</xref>. Genetically, robustness is highlighted by the fact that while ∼80% of budding yeast (<italic>Saccharomyces cerevisiae</italic>) genes are not required for proliferation in rich medium <xref rid="b0060" ref-type="bibr">[14]</xref>, most single mutants are sensitive for an additional perturbation (i.e., a synthetic lethal interaction) such as knockout of a second gene, a change in culture conditions or exposure to a chemical compound <xref rid="b0030 b0065" ref-type="bibr">[8,15]</xref>. Thus synthetic lethality can be thought of as a feature of genetic robustness.</p>
      <p>Genetic robustness is established via various buffering mechanisms, such as functional redundancy and proteins known as capacitors. In diploid organisms, redundancy is the simplest type of buffering due to the presence of two alleles in the genome. Indeed, many heterozygous knockout mice are not discernable from their wild-type littermates. Redundancy is also provided by genes that have a common ancestor and can still partially perform the same task (e.g., AKT1 and AKT2), although in yeast this type of redundancy is relatively rare, explaining only a small fraction of genetic interactions <xref rid="b0065" ref-type="bibr">[15]</xref>. Instead, robustness is mostly provided by non-homologous genes operating in the same cellular process or in back-up pathways (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). For example, a large scale RNA interference (RNAi) screen to identify human genes that were synthetic lethal with low concentrations of the mitotic inhibitor paclitaxel found some coding for proteins of the mitotic spindle apparatus itself as well as others coding for proteins of the proteasome, which is involved in protein-degradation, indicating that mitosis is buffered at several different levels <xref rid="b0070" ref-type="bibr">[16]</xref>.</p>
      <p>Another interesting type of buffering is provided by so-called “capacitors” like heat shock proteins and chromatin regulators that can mask the effects of many different mutations (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) <xref rid="b0065 b0075 b0080" ref-type="bibr">[15,17,18]</xref>. Therefore, capacitors display many synthetic lethal interactions. The role of heat shock proteins in the buffering of genetic variations is believed to stem from their ability to promote proper folding of mutated proteins. Capacitors may also explain the effectiveness of HSP90 and histone deacetylase inhibitors as anticancer drugs, a topic that is discussed below <xref rid="b0085" ref-type="bibr">[19]</xref>.</p>
      <p>Thus, cellular systems maintain homeostasis partly by ensuring that processes do not depend on any single component, which could easily be perturbed by mutation or environmental effects, setting the scene for synthetic lethal interactions <xref rid="b0315 b0045 b0055" ref-type="bibr">[4,11,13]</xref>.</p>
    </sec>
    <sec id="s0015">
      <label>3</label>
      <title>Synthetic lethality provides insights into gene function and drug action</title>
      <p>The true potential of synthetic lethality has been most extensively realized in yeast <xref rid="b0035" ref-type="bibr">[9]</xref>. Here, the large-scale quantitative mapping of synthetic lethal interactions has reached genome-wide scale and the resulting comprehensive genetic interaction networks are a rich source for the functional annotation of genes <xref rid="b0030 b0065" ref-type="bibr">[8,15]</xref>. This is because genes that act in the same process often buffer each other, so they also tend to cluster together in these networks and gene function or even enzyme–substrate relationships can be inferred <xref rid="b0005 b0090" ref-type="bibr">[3,20]</xref>. Clearly, the elucidation of similar comprehensive synthetic lethal interaction networks in human cells would be very attractive, particularly as the majority of genes have still not been assigned a function a decade after the first draft of the human genome was generated.</p>
      <p>Drugs also display synthetic lethal interactions with genes, which can be used to study their effects on cells <xref rid="b0020" ref-type="bibr">[6]</xref>. Indeed, drug-gene interaction screens in yeast have been used extensively to study the mechanism of action of drugs and similar studies in human cells would be invaluable <xref rid="b0095 b0100 b0105 b0110" ref-type="bibr">[21–24]</xref>. This is particularly important because for many drugs that are used in the clinic not all protein targets are known, which is essential for understanding their unwanted side effects.</p>
      <p>Knowledge of drug–gene synthetic lethal interactions may also be used to design combination therapies and predict synergistic/sensitizer drugs <xref rid="b0070 b0115 b0120 b0125 b0130" ref-type="bibr">[16,25–28]</xref>. This is particularly important in cancer and infectious diseases, as drug combinations with distinct cellular targets can limit treatment resistance and synergistic drugs can be used at much lower concentrations to achieve the same biological effect, thereby limiting side effects <xref rid="b0135" ref-type="bibr">[29]</xref>.</p>
    </sec>
    <sec id="s0020">
      <label>4</label>
      <title>Synthetic lethality provides a framework for the mechanism of action of chemotherapy</title>
      <p>The notion that conventional chemotherapeutics work by targeting fast dividing cells is not the whole story and a molecular understanding of why certain cancer cells respond to a specific chemotherapeutic while others are resistant, remains largely unexplained <xref rid="b0025" ref-type="bibr">[7]</xref>. It is also not apparent why some cancers are sensitive for drugs such as Bortezomib, Vorinostat and Geldanamycin that inhibit the proteasome, histone deacetylases and HSP90 respectively, since these cellular targets are not directly implicated in tumorigenesis. Instead the effectiveness of these chemotherapies may be due to synthetic lethality <xref rid="b0015 b0025" ref-type="bibr">[5,7]</xref>. For example, given that genomic instability, defective DNA repair, and deregulated transcription are some of the hallmarks of cancer, drugs that further perturb these processes may be specifically toxic (i.e., synthetically lethal) in cancer cells. In other words, the molecular changes in the cancer cells have strained the buffering capacity of these systems.</p>
      <p>Identifying new synthetic lethal interactions found in specific cancer types and individual tumors, particularly a map of the synthetic interactions between DNA repair pathways and DNA damage-based cancer therapies, would be an invaluable aid for guiding therapy choice.</p>
    </sec>
    <sec id="s0025">
      <label>5</label>
      <title>Synthetic lethality and new opportunities for cancer therapeutics</title>
      <p>Although much is now known about the large number of molecular aberrations that are found in cancer it can be difficult to directly translate this knowledge into new therapies. A major hurdle in drug discovery is that most oncogenes are not easily accessible for inhibition by small molecules and the restoration of loss-of-function changes in tumor suppressor genes in patients is nearly impossible <xref rid="b0015" ref-type="bibr">[5]</xref>. In their seminal paper, Lee Hartwell and Stephen Friend proposed that synthetic lethality may provide a solution <xref rid="b0140" ref-type="bibr">[30]</xref>. They reasoned as follows: Cancer cells have acquired molecular changes that distinguish them from their wild-type counterparts. Consequently, cancer cells have been “re-wired”, exposing new genetic vulnerabilities. Synthetic lethal interaction partners of cancer-associated molecular changes should therefore offer excellent therapeutic opportunities.</p>
      <p>This notion is somewhat related to oncogene addiction, the observation that tumorigenesis cells become “addicted” to their genetic changes and thus vulnerable for the sudden inactivation of oncogenes or reactivation of tumor suppressors <xref rid="b0145" ref-type="bibr">[31]</xref>. To discriminate between synthetic lethal interactions and oncogene addiction, the former has therefore also been called “non-oncogene addiction” <xref rid="b0025" ref-type="bibr">[7]</xref>.</p>
      <p>The great potential of synthetic lethality-based cancer therapy is best illustrated by a landmark achievement concerning the tumor suppressor and DNA repair genes BRCA1 and BRCA2, mutations in which can cause breast and ovarian cancer. The BRCA genes display synthetic lethality with another DNA repair enzyme called PARP and the tumors of patients carrying these mutations could be successfully treated using a chemical PARP inhibitor with remarkably mild side effects <xref rid="b0150 b0155 b0160 b0165" ref-type="bibr">[32–35]</xref>. Interestingly, recent studies have suggested various other synthetic lethal partners of PARP, including the tumor suppressor PTEN <xref rid="b0130 b0170 b0175 b0180" ref-type="bibr">[28,36–38]</xref>.</p>
      <p>The BRCA/PARP case has become the paradigm for a new class of rational cancer therapies based on the synthetic lethality concept <xref rid="b0185 b0190 b0195" ref-type="bibr">[39–41]</xref>. Furthermore, it calls for a comprehensive effort to identify synthetic lethalities in human cells and the challenge now remains to adapt newly-available methods to identify them.</p>
    </sec>
    <sec id="s0030">
      <label>6</label>
      <title>In silico prediction and evolutionary conservation of synthetic lethality</title>
      <p>Based on yeast studies it is known that some characteristics make two genes more likely to display a genetic interaction. For instance, shared localization, physical interaction and co-expression are some of the predictors of synthetic lethality <xref rid="b0200" ref-type="bibr">[42]</xref>. But even with the high-quality data from yeast, prediction algorithms are unreliable, and empirical testing remains the only way to confidently and comprehensively identify genetic interactions <xref rid="b0035" ref-type="bibr">[9]</xref>.</p>
      <p>As a large number of yeast genes have human orthologs, and genome scale genetic networks are available in yeast, it is interesting to explore the evolutionary conservation of genetic interactions. Remarkably, <italic>S. cerevisiae</italic> and <italic>Saccharomyces pombe</italic>, yeast species that diverged 300–600 million years ago and differ in many biological properties, share approximately 30% of their genetic interactions, suggesting significant conservation <xref rid="b0205 b0210" ref-type="bibr">[43,44]</xref>.</p>
      <p>The utility of yeast for the accurate prediction of synthetic lethality in higher eukaryotes remains unclear. Although a study of spindle assembly checkpoint genes found that about 25% of yeast synthetic lethalities were conserved in the nematode <italic>Caenorhabdites elegans</italic> <xref rid="b0215" ref-type="bibr">[45]</xref>, several larger-scale studies found as few as 1% of interactions conserved between these two organisms, questioning the general conservation of synthetic lethality <xref rid="b0220 b0225" ref-type="bibr">[46,47]</xref>. Some of the weak conservation may be explained by technical limitations or perhaps genetic interactions are more likely to be conserved only in certain biological processes such as chromosome segregation. Indeed, the few studies that have successfully used yeast genetic interactions to predict interactions in mammalian cells suggest there is limited conservation <xref rid="b0105 b0230 b0235 b0240" ref-type="bibr">[23,48–50]</xref>. Future studies will undoubtedly shed more light on this important question but in the meantime, the only way to systematically identify synthetic lethalities in higher eukaryotes, including humans, is to use an empirical approach.</p>
    </sec>
    <sec id="s0035">
      <label>7</label>
      <title>Synthetic lethality screen approaches in human cells</title>
      <p>Until recently, synthetic lethality screens were mostly limited to screens using chemical compounds but a scalable approach to identify gene-gene interactions was lacking <xref rid="b0125 b0245 b0250" ref-type="bibr">[27,51,52]</xref>. With the discovery of RNAi it has become feasible to systematically identify synthetic lethal interactions in human cells, and a variety of different screening strategies have recently been developed.</p>
      <p>The two general approaches in classical genetics that are used to link phenotype with genotype (referred to as <italic>forward</italic> and <italic>reverse</italic>) can also be used to classify synthetic lethality screens in human cells (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). Traditional forward genetics starts with a phenotype of interest, for instance obtained by screening a collection of mutants, and aims to identify the responsible gene. Conversely, reverse genetics takes a defined mutant, for example a knockout mouse, and looks for the functional consequence of this genetic change. In synthetic lethality screens, the forward approach uses the genetic variability in a collection of cancer cell lines whereas in the reverse tactic a single specific genetic change is engineered resulting in an isogenic cell line pair. In both cases the next step is to identify genes that are required for cell viability using RNAi-mediated knockdown and linking these to the genotypic differences.</p>
      <p>Both approaches have been successfully employed but have strengths and weaknesses. A caveat of the forward approach is that cell lines typically show a plethora of heterogeneous aberrations, making it challenging to correlate specific genetic changes with the identified sensitivity to a certain knockdown. Reverse genetic approaches have the advantage that every sensitivity is most likely a true genetic interaction. However, as the isogenic cell line was artificially created the genetic background and cellular state does not strictly reflect a “normal” cancer cell. Therefore, the genetic interactions do not necessarily mirror those in cancer cells that naturally harbor the genetic defect.</p>
      <p>A second methodological distinction is based on the screening format. To circumvent the practical limitations of screening individual short hairpin (shRNA) vectors in a single-well, several groups have developed pooled methods that are inspired by technologies pioneered in yeast to genetically barcode knockout clones so they can still be accurately identified even within a mixed population of cells <xref rid="b0255 b0260 b0265 b0270" ref-type="bibr">[53–56]</xref>. Such screens are much easier to handle than large-scale single well screens and thus have a higher throughput (<xref rid="f0020" ref-type="fig">Fig. 4</xref>).</p>
    </sec>
    <sec id="s0040">
      <label>8</label>
      <title>Examples of synthetic lethality screens</title>
      <p>In the last year, several RNAi screening approaches were reported used to identify synthetic lethal interactions with oncogenic RAS, which is frequently mutated in a variety of cancers but difficult to target directly using small molecule inhibitors and therefore attractive for a synthetic lethal therapy. As well as being some of the most comprehensive human synthetic lethality screens to date, these studies also effectively highlight the different screening approaches that are currently available. In addition, they offer an opportunity to discuss some of the current limitations and challenges of synthetic lethality screens in human cells.</p>
      <p>In two papers published by the groups of William Hahn and Gary Gilliland, a forward, single-well single-gene approach was employed <xref rid="b0275 b0280" ref-type="bibr">[57,58]</xref>. In the larger of the two screens, kinases, phosphatases and known cancer-relevant genes (∼1000 in total) were inhibited by RNAi in a panel of 19 RAS mutant and wild type cell lines <xref rid="b0280" ref-type="bibr">[58]</xref>. ShRNAs were selected by supervised clustering for follow-up experiments and the hits after a second round of validation in a panel of lung cancer cell lines were RAS itself and the NF-κB activator TBK1, which is consistent with previously reported observations that RAS transformed cells require active NF-κB signaling and that RAS activates TBK1 <xref rid="b0285 b0290" ref-type="bibr">[59,60]</xref>. In addition, the therapeutic potential of targeting the newly identified synthetic lethal interaction between the NF-kappa B pathway and oncogenic RAS was demonstrated in a mouse model of lung cancer <xref rid="b0295" ref-type="bibr">[61]</xref>.</p>
      <p>In another study, Stephen Elledge and colleagues undertook an alternative reverse pooled approach to identify synthetic lethal RAS interactors <xref rid="b0300" ref-type="bibr">[62]</xref>. Using a clone of the DLD1 colorectal cancer cell line differing only in the mutational status of RAS, a so-called isogenic clone, they screened almost 75 000 shRNA vectors (covering most of the genes in the human genome) for differential sensitivities (<xref rid="f0020" ref-type="fig">Fig. 4</xref>). Interestingly, the putative RAS synthetic lethal interactors that were identified are involved in diverse processes including proteasome function, suggesting that RAS-induced transformation requires substantial buffering. In particular, the authors found that RAS mutant cells are hypersensitive to inhibition of the mitosis checkpoint protein PLK1. In a similar effort, the laboratory of Julian Downward recently performed a screen in isogenic colorectal carcinoma HCT116 cells with a pooled library targeting 2500 genes and identified the transcription factor SNAIL2 to be required only in RAS mutant cells <xref rid="b0305" ref-type="bibr">[63]</xref>.</p>
    </sec>
    <sec id="s0045">
      <label>9</label>
      <title>Limitations of RNAi screens and outlook</title>
      <p>The overlap between the synthetic lethalities in the mentioned RAS synthetic lethality screens is very limited. Some of this may be due to the use of different cell lines for the screens and technical approach but given that ∼75% of the interactions identified in the genome-wide DLD1 screen also displayed an effect in HCT116 cells this is unlikely to be the complete explanation <xref rid="b0300" ref-type="bibr">[62]</xref>. Rather, the use of different shRNA libraries that target only partially overlapping genes and inhibit gene expression with different efficiencies, provides a technical explanation and indicates a large number of false-negatives in the screens. Indeed, the variability in knockdown efficiency and the fact that RNAi typically only results in 70–90% inhibition of expression highlights a weakness of this tool. In addition, the fact that RNAi screens are plagued with off target effects provides an explanation for false positives. Therefore, the availability and further development of powerful screening technologies, including better characterized knockdown libraries, will continue to be a driving force behind human functional genetics. Particularly, new technologies such as a method for the large-scale generation of human knockout cells will add to the current tool-box and may finally provide yeast-like genetics in human cells <xref rid="b0310" ref-type="bibr">[64]</xref>.</p>
      <p>Although the mentioned new and other known synthetic lethal interactions may provide handles for novel therapies, most of the described genetic interactions in cancer cells do not strictly adhere to the definition of synthetic lethality which demands that only the combination of two perturbations results in lethality. Frequently the perturbations are also toxic on their own, which would limit the specificity of the drug and likely introduce unwanted side-effects, or the interaction is more accurately described as synthetic sick so the cancer cells would not be completely eliminated. Analogous to the therapeutic window for drugs, i.e., the safe and effective dose range, “the synthetic lethality window” of the genetic interaction will be important for its potential as a therapy (<xref rid="f0025" ref-type="fig">Fig. 5</xref>). For example, with the BRCA-PARP synthetic lethal interaction, BRCA mutant cells are some two orders of magnitude more sensitive to PARP inhibitors than non-mutant cells and this strong responsiveness is probably key to its clinical success. It is currently unclear how common this type of strong genetic interaction is in human cells.</p>
      <p>In summary, synthetic lethality is a valuable concept to understand the functions of genes, the mechanism of action of drugs and their interactions, and has immediate relevance for cancer therapy. In recent years it has brought inspiration to search for a new class of anti-cancer therapies and future treatment strategies will increasingly consist of combination therapies based on personalized tumor vulnerabilities, including synthetic lethality. Aided by powerful genetic tools, there is little doubt that we are at the brink of an explosion of synthetic lethality information in human cells.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="b0320">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bridges</surname>
              <given-names>C.B.</given-names>
            </name>
          </person-group>
          <article-title>The origin of variation</article-title>
          <source>Amer Nat</source>
          <volume>56</volume>
          <year>1922</year>
          <fpage>51</fpage>
          <lpage>63</lpage>
        </element-citation>
      </ref>
      <ref id="b0325">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dobzhansky</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Genetics of natural populations. XIII. Recombination and variability in populations of <italic>Drosphila pseudoobscura</italic></article-title>
          <source>Genetics</source>
          <volume>31</volume>
          <year>1946</year>
          <fpage>269</fpage>
          <lpage>290</lpage>
        </element-citation>
      </ref>
      <ref id="b0005">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boone</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bussey</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>B.J.</given-names>
            </name>
          </person-group>
          <article-title>Exploring genetic interactions and networks with yeast</article-title>
          <source>Nat Rev Genet</source>
          <volume>8</volume>
          <year>2007</year>
          <fpage>437</fpage>
          <lpage>449</lpage>
          <pub-id pub-id-type="pmid">17510664</pub-id>
        </element-citation>
      </ref>
      <ref id="b0315">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hartman</surname>
              <given-names>J.L.T.</given-names>
            </name>
            <name>
              <surname>Garvik</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Hartwell</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Principles for the buffering of genetic variation</article-title>
          <source>Science</source>
          <volume>291</volume>
          <year>2001</year>
          <fpage>1001</fpage>
          <lpage>1004</lpage>
          <pub-id pub-id-type="pmid">11232561</pub-id>
        </element-citation>
      </ref>
      <ref id="b0015">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaelin</surname>
              <given-names>W.G.</given-names>
              <suffix>Jr.</suffix>
            </name>
          </person-group>
          <article-title>The concept of synthetic lethality in the context of anticancer therapy</article-title>
          <source>Nat Rev Cancer</source>
          <volume>5</volume>
          <year>2005</year>
          <fpage>689</fpage>
          <lpage>698</lpage>
          <pub-id pub-id-type="pmid">16110319</pub-id>
        </element-citation>
      </ref>
      <ref id="b0020">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lehar</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Stockwell</surname>
              <given-names>B.R.</given-names>
            </name>
            <name>
              <surname>Giaever</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Nislow</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Combination chemical genetics</article-title>
          <source>Nat Chem Biol</source>
          <volume>4</volume>
          <year>2008</year>
          <fpage>674</fpage>
          <lpage>681</lpage>
          <pub-id pub-id-type="pmid">18936752</pub-id>
        </element-citation>
      </ref>
      <ref id="b0025">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luo</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Solimini</surname>
              <given-names>N.L.</given-names>
            </name>
            <name>
              <surname>Elledge</surname>
              <given-names>S.J.</given-names>
            </name>
          </person-group>
          <article-title>Principles of cancer therapy: oncogene and non-oncogene addiction</article-title>
          <source>Cell</source>
          <volume>136</volume>
          <year>2009</year>
          <fpage>823</fpage>
          <lpage>837</lpage>
          <pub-id pub-id-type="pmid">19269363</pub-id>
        </element-citation>
      </ref>
      <ref id="b0030">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hillenmeyer</surname>
              <given-names>M.E.</given-names>
            </name>
          </person-group>
          <article-title>The chemical genomic portrait of yeast: uncovering a phenotype for all genes</article-title>
          <source>Science</source>
          <volume>320</volume>
          <year>2008</year>
          <fpage>362</fpage>
          <lpage>365</lpage>
          <pub-id pub-id-type="pmid">18420932</pub-id>
        </element-citation>
      </ref>
      <ref id="b0035">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dixon</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Costanzo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Baryshnikova</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Boone</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Systematic mapping of genetic interaction networks</article-title>
          <source>Annu Rev Genet</source>
          <volume>43</volume>
          <year>2009</year>
          <fpage>601</fpage>
          <lpage>625</lpage>
          <pub-id pub-id-type="pmid">19712041</pub-id>
        </element-citation>
      </ref>
      <ref id="b0040">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaelin</surname>
              <given-names>W.G.</given-names>
              <suffix>Jr.</suffix>
            </name>
          </person-group>
          <article-title>Synthetic lethality: a framework for the development of wiser cancer therapeutics</article-title>
          <source>Genome Med</source>
          <volume>1</volume>
          <year>2009</year>
          <fpage>99</fpage>
          <pub-id pub-id-type="pmid">19863774</pub-id>
        </element-citation>
      </ref>
      <ref id="b0045">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Masel</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Siegal</surname>
              <given-names>M.L.</given-names>
            </name>
          </person-group>
          <article-title>Robustness: mechanisms and consequences</article-title>
          <source>Trends Genet</source>
          <volume>25</volume>
          <year>2009</year>
          <fpage>395</fpage>
          <lpage>403</lpage>
          <pub-id pub-id-type="pmid">19717203</pub-id>
        </element-citation>
      </ref>
      <ref id="b0050">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gibson</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Decanalization and the origin of complex disease</article-title>
          <source>Nat Rev Genet</source>
          <volume>10</volume>
          <year>2009</year>
          <fpage>134</fpage>
          <lpage>140</lpage>
          <pub-id pub-id-type="pmid">19119265</pub-id>
        </element-citation>
      </ref>
      <ref id="b0055">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kirschner</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gerhart</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Evolvability</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>95</volume>
          <year>1998</year>
          <fpage>8420</fpage>
          <lpage>8427</lpage>
          <pub-id pub-id-type="pmid">9671692</pub-id>
        </element-citation>
      </ref>
      <ref id="b0060">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winzeler</surname>
              <given-names>E.A.</given-names>
            </name>
          </person-group>
          <article-title>Functional characterization of the S</article-title>
          <source>Cerevisiae genome by gene deletion and parallel analysis. Science</source>
          <volume>285</volume>
          <year>1999</year>
          <fpage>901</fpage>
          <lpage>906</lpage>
        </element-citation>
      </ref>
      <ref id="b0065">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Costanzo</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The genetic landscape of a cell</article-title>
          <source>Science</source>
          <volume>327</volume>
          <year>2010</year>
          <fpage>425</fpage>
          <lpage>431</lpage>
          <pub-id pub-id-type="pmid">20093466</pub-id>
        </element-citation>
      </ref>
      <ref id="b0070">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whitehurst</surname>
              <given-names>A.W.</given-names>
            </name>
          </person-group>
          <article-title>Synthetic lethal screen identification of chemosensitizer loci in cancer cells</article-title>
          <source>Nature</source>
          <volume>446</volume>
          <year>2007</year>
          <fpage>815</fpage>
          <lpage>819</lpage>
          <pub-id pub-id-type="pmid">17429401</pub-id>
        </element-citation>
      </ref>
      <ref id="b0075">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rutherford</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Lindquist</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Hsp90 as a capacitor for morphological evolution</article-title>
          <source>Nature</source>
          <volume>396</volume>
          <year>1998</year>
          <fpage>336</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="pmid">9845070</pub-id>
        </element-citation>
      </ref>
      <ref id="b0080">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lehner</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Crombie</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Tischler</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Fortunato</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>A.G.</given-names>
            </name>
          </person-group>
          <article-title>Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways</article-title>
          <source>Nat Genet</source>
          <volume>38</volume>
          <year>2006</year>
          <fpage>896</fpage>
          <lpage>903</lpage>
          <pub-id pub-id-type="pmid">16845399</pub-id>
        </element-citation>
      </ref>
      <ref id="b0085">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whitesell</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Lindquist</surname>
              <given-names>S.L.</given-names>
            </name>
          </person-group>
          <article-title>HSP90 and the chaperoning of cancer</article-title>
          <source>Nat Rev Cancer</source>
          <volume>5</volume>
          <year>2005</year>
          <fpage>761</fpage>
          <lpage>772</lpage>
          <pub-id pub-id-type="pmid">16175177</pub-id>
        </element-citation>
      </ref>
      <ref id="b0090">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fiedler</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Functional organization of the <italic>S. cerevisiae</italic> phosphorylation network</article-title>
          <source>Cell</source>
          <volume>136</volume>
          <year>2009</year>
          <fpage>952</fpage>
          <lpage>963</lpage>
          <pub-id pub-id-type="pmid">19269370</pub-id>
        </element-citation>
      </ref>
      <ref id="b0095">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lum</surname>
              <given-names>P.Y.</given-names>
            </name>
          </person-group>
          <article-title>Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes</article-title>
          <source>Cell</source>
          <volume>116</volume>
          <year>2004</year>
          <fpage>121</fpage>
          <lpage>137</lpage>
          <pub-id pub-id-type="pmid">14718172</pub-id>
        </element-citation>
      </ref>
      <ref id="b0100">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>St Onge</surname>
              <given-names>R.P.</given-names>
            </name>
          </person-group>
          <article-title>Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions</article-title>
          <source>Nat Genet</source>
          <volume>39</volume>
          <year>2007</year>
          <fpage>199</fpage>
          <lpage>206</lpage>
          <pub-id pub-id-type="pmid">17206143</pub-id>
        </element-citation>
      </ref>
      <ref id="b0105">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Chemical-genetic profiling of imidazo[1, 2-a]pyridines and -pyrimidines reveals target pathways conserved between yeast and human cells</article-title>
          <source>PLoS Genet</source>
          <volume>4</volume>
          <year>2008</year>
          <fpage>e1000284</fpage>
          <pub-id pub-id-type="pmid">19043571</pub-id>
        </element-citation>
      </ref>
      <ref id="b0110">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ericson</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Gebbia</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Heisler</surname>
              <given-names>L.E.</given-names>
            </name>
            <name>
              <surname>Wildenhain</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Tyers</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Giaever</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Nislow</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast</article-title>
          <source>PLoS Genet</source>
          <volume>4</volume>
          <year>2008</year>
          <fpage>e1000151</fpage>
          <pub-id pub-id-type="pmid">18688276</pub-id>
        </element-citation>
      </ref>
      <ref id="b0115">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guo</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota</article-title>
          <source>Cancer Res</source>
          <volume>68</volume>
          <year>2008</year>
          <fpage>7403</fpage>
          <lpage>7408</lpage>
          <pub-id pub-id-type="pmid">18794128</pub-id>
        </element-citation>
      </ref>
      <ref id="b0120">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turcotte</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Sutphin</surname>
              <given-names>P.D.</given-names>
            </name>
            <name>
              <surname>Hay</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Denny</surname>
              <given-names>W.A.</given-names>
            </name>
            <name>
              <surname>Giaccia</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy</article-title>
          <source>Cancer Cell</source>
          <volume>14</volume>
          <year>2008</year>
          <fpage>90</fpage>
          <lpage>102</lpage>
          <pub-id pub-id-type="pmid">18598947</pub-id>
        </element-citation>
      </ref>
      <ref id="b0125">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dolma</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lessnick</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Hahn</surname>
              <given-names>W.C.</given-names>
            </name>
            <name>
              <surname>Stockwell</surname>
              <given-names>B.R.</given-names>
            </name>
          </person-group>
          <article-title>Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells</article-title>
          <source>Cancer Cell</source>
          <volume>3</volume>
          <year>2003</year>
          <fpage>285</fpage>
          <lpage>296</lpage>
          <pub-id pub-id-type="pmid">12676586</pub-id>
        </element-citation>
      </ref>
      <ref id="b0130">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turner</surname>
              <given-names>N.C.</given-names>
            </name>
          </person-group>
          <article-title>A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor</article-title>
          <source>EMBO J</source>
          <volume>27</volume>
          <year>2008</year>
          <fpage>1368</fpage>
          <lpage>1377</lpage>
          <pub-id pub-id-type="pmid">18388863</pub-id>
        </element-citation>
      </ref>
      <ref id="b0135">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zimmermann</surname>
              <given-names>G.R.</given-names>
            </name>
            <name>
              <surname>Lehar</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Keith</surname>
              <given-names>C.T.</given-names>
            </name>
          </person-group>
          <article-title>Multi-target therapeutics: when the whole is greater than the sum of the parts</article-title>
          <source>Drug Discov Today</source>
          <volume>12</volume>
          <year>2007</year>
          <fpage>34</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">17198971</pub-id>
        </element-citation>
      </ref>
      <ref id="b0140">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hartwell</surname>
              <given-names>L.H.</given-names>
            </name>
            <name>
              <surname>Szankasi</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>A.W.</given-names>
            </name>
            <name>
              <surname>Friend</surname>
              <given-names>S.H.</given-names>
            </name>
          </person-group>
          <article-title>Integrating genetic approaches into the discovery of anticancer drugs</article-title>
          <source>Science</source>
          <volume>278</volume>
          <year>1997</year>
          <fpage>1064</fpage>
          <lpage>1068</lpage>
          <pub-id pub-id-type="pmid">9353181</pub-id>
        </element-citation>
      </ref>
      <ref id="b0145">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinstein</surname>
              <given-names>I.B.</given-names>
            </name>
          </person-group>
          <article-title>Cancer. Addiction to oncogenes–the Achilles heal of cancer</article-title>
          <source>Science</source>
          <volume>297</volume>
          <year>2002</year>
          <fpage>63</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="pmid">12098689</pub-id>
        </element-citation>
      </ref>
      <ref id="b0150">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farmer</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title>
          <source>Nature</source>
          <volume>434</volume>
          <year>2005</year>
          <fpage>917</fpage>
          <lpage>921</lpage>
          <pub-id pub-id-type="pmid">15829967</pub-id>
        </element-citation>
      </ref>
      <ref id="b0155">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bryant</surname>
              <given-names>H.E.</given-names>
            </name>
          </person-group>
          <article-title>Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</article-title>
          <source>Nature</source>
          <volume>434</volume>
          <year>2005</year>
          <fpage>913</fpage>
          <lpage>917</lpage>
          <pub-id pub-id-type="pmid">15829966</pub-id>
        </element-citation>
      </ref>
      <ref id="b0160">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fong</surname>
              <given-names>P.C.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</article-title>
          <source>N Engl J Med</source>
          <volume>361</volume>
          <year>2009</year>
          <fpage>123</fpage>
          <lpage>134</lpage>
          <pub-id pub-id-type="pmid">19553641</pub-id>
        </element-citation>
      </ref>
      <ref id="b0165">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fong</surname>
              <given-names>P.C.</given-names>
            </name>
          </person-group>
          <article-title>Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval</article-title>
          <source>J Clin Oncol</source>
          <volume>28</volume>
          <year>2010</year>
          <fpage>2512</fpage>
          <lpage>2519</lpage>
          <pub-id pub-id-type="pmid">20406929</pub-id>
        </element-citation>
      </ref>
      <ref id="b0170">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wiltshire</surname>
              <given-names>T.D.</given-names>
            </name>
            <name>
              <surname>Lovejoy</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>O’Connor</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Cortez</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair</article-title>
          <source>J Biol Chem</source>
          <volume>285</volume>
          <year>2010</year>
          <fpage>14565</fpage>
          <lpage>14571</lpage>
          <pub-id pub-id-type="pmid">20233726</pub-id>
        </element-citation>
      </ref>
      <ref id="b0175">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mendes-Pereira</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <article-title>Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors</article-title>
          <source>EMBO Mol Med</source>
          <volume>1</volume>
          <year>2009</year>
          <fpage>315</fpage>
          <lpage>322</lpage>
          <pub-id pub-id-type="pmid">20049735</pub-id>
        </element-citation>
      </ref>
      <ref id="b0180">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orsburn</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Escudero</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Prakash</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gesheva</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Huso</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Franco</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Differential requirement for H2AX and 53BP1 in organismal development and genome maintenance in the absence of poly(ADP)ribosyl polymerase 1</article-title>
          <source>Mol Cell Biol</source>
          <volume>30</volume>
          <year>2010</year>
          <fpage>2341</fpage>
          <lpage>2352</lpage>
          <pub-id pub-id-type="pmid">20231360</pub-id>
        </element-citation>
      </ref>
      <ref id="b0185">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sandhu</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Yap</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>de Bono</surname>
              <given-names>J.S.</given-names>
            </name>
          </person-group>
          <article-title>Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective</article-title>
          <source>Eur J Cancer</source>
          <volume>46</volume>
          <year>2010</year>
          <fpage>9</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">19926276</pub-id>
        </element-citation>
      </ref>
      <ref id="b0190">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ashworth</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair</article-title>
          <source>J Clin Oncol</source>
          <volume>26</volume>
          <year>2008</year>
          <fpage>3785</fpage>
          <lpage>3790</lpage>
          <pub-id pub-id-type="pmid">18591545</pub-id>
        </element-citation>
      </ref>
      <ref id="b0195">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iglehart</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Silver</surname>
              <given-names>D.P.</given-names>
            </name>
          </person-group>
          <article-title>Synthetic lethality–a new direction in cancer-drug development</article-title>
          <source>N Engl J Med</source>
          <volume>361</volume>
          <year>2009</year>
          <fpage>189</fpage>
          <lpage>191</lpage>
          <pub-id pub-id-type="pmid">19553640</pub-id>
        </element-citation>
      </ref>
      <ref id="b0200">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wong</surname>
              <given-names>S.L.</given-names>
            </name>
          </person-group>
          <article-title>Combining biological networks to predict genetic interactions</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>101</volume>
          <year>2004</year>
          <fpage>15682</fpage>
          <lpage>15687</lpage>
          <pub-id pub-id-type="pmid">15496468</pub-id>
        </element-citation>
      </ref>
      <ref id="b0205">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roguev</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast</article-title>
          <source>Science</source>
          <volume>322</volume>
          <year>2008</year>
          <fpage>405</fpage>
          <lpage>410</lpage>
          <pub-id pub-id-type="pmid">18818364</pub-id>
        </element-citation>
      </ref>
      <ref id="b0210">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dixon</surname>
              <given-names>S.J.</given-names>
            </name>
          </person-group>
          <article-title>Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>105</volume>
          <year>2008</year>
          <fpage>16653</fpage>
          <lpage>16658</lpage>
          <pub-id pub-id-type="pmid">18931302</pub-id>
        </element-citation>
      </ref>
      <ref id="b0215">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tarailo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tarailo</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <article-title>Synthetic lethal interactions identify phenotypic “interologs” of the spindle assembly checkpoint components</article-title>
          <source>Genetics</source>
          <volume>177</volume>
          <year>2007</year>
          <fpage>2525</fpage>
          <lpage>2530</lpage>
          <pub-id pub-id-type="pmid">18073444</pub-id>
        </element-citation>
      </ref>
      <ref id="b0220">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tischler</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lehner</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>A.G.</given-names>
            </name>
          </person-group>
          <article-title>Evolutionary plasticity of genetic interaction networks</article-title>
          <source>Nat Genet</source>
          <volume>40</volume>
          <year>2008</year>
          <fpage>390</fpage>
          <lpage>391</lpage>
          <pub-id pub-id-type="pmid">18362882</pub-id>
        </element-citation>
      </ref>
      <ref id="b0225">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Byrne</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Weirauch</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Koeva</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Dixon</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Stuart</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Roy</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>A global analysis of genetic interactions in Caenorhabditis elegans</article-title>
          <source>J Biol</source>
          <volume>6</volume>
          <year>2007</year>
          <fpage>8</fpage>
          <pub-id pub-id-type="pmid">17897480</pub-id>
        </element-citation>
      </ref>
      <ref id="b0230">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McManus</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Barrett</surname>
              <given-names>I.J.</given-names>
            </name>
            <name>
              <surname>Nouhi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Hieter</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>106</volume>
          <year>2009</year>
          <fpage>3276</fpage>
          <lpage>3281</lpage>
          <pub-id pub-id-type="pmid">19218431</pub-id>
        </element-citation>
      </ref>
      <ref id="b0235">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conde-Pueyo</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Munteanu</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sole</surname>
              <given-names>R.V.</given-names>
            </name>
            <name>
              <surname>Rodriguez-Caso</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Human synthetic lethal inference as potential anti-cancer target gene detection</article-title>
          <source>BMC Syst Biol</source>
          <volume>3</volume>
          <year>2009</year>
          <fpage>116</fpage>
          <pub-id pub-id-type="pmid">20015360</pub-id>
        </element-citation>
      </ref>
      <ref id="b0240">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McLellan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>O’Neil</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Tarailo</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Stoepel</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bryan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hieter</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Synthetic lethal genetic interactions that decrease somatic cell proliferation in Caenorhabditis elegans identify the alternative RFC CTF18 as a candidate cancer drug target</article-title>
          <source>Mol Biol Cell</source>
          <volume>20</volume>
          <year>2009</year>
          <fpage>5306</fpage>
          <lpage>5313</lpage>
          <pub-id pub-id-type="pmid">19846659</pub-id>
        </element-citation>
      </ref>
      <ref id="b0245">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torrance</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Agrawal</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Vogelstein</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Kinzler</surname>
              <given-names>K.W.</given-names>
            </name>
          </person-group>
          <article-title>Use of isogenic human cancer cells for high-throughput screening and drug discovery</article-title>
          <source>Nat Biotechnol</source>
          <volume>19</volume>
          <year>2001</year>
          <fpage>940</fpage>
          <lpage>945</lpage>
          <pub-id pub-id-type="pmid">11581659</pub-id>
        </element-citation>
      </ref>
      <ref id="b0250">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shoemaker</surname>
              <given-names>R.H.</given-names>
            </name>
          </person-group>
          <article-title>The NCI60 human tumour cell line anticancer drug screen</article-title>
          <source>Nat Rev Cancer</source>
          <volume>6</volume>
          <year>2006</year>
          <fpage>813</fpage>
          <lpage>823</lpage>
          <pub-id pub-id-type="pmid">16990858</pub-id>
        </element-citation>
      </ref>
      <ref id="b0255">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ngo</surname>
              <given-names>V.N.</given-names>
            </name>
          </person-group>
          <article-title>A loss-of-function RNA interference screen for molecular targets in cancer</article-title>
          <source>Nature</source>
          <volume>441</volume>
          <year>2006</year>
          <fpage>106</fpage>
          <lpage>110</lpage>
          <pub-id pub-id-type="pmid">16572121</pub-id>
        </element-citation>
      </ref>
      <ref id="b0260">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schlabach</surname>
              <given-names>M.R.</given-names>
            </name>
          </person-group>
          <article-title>Cancer proliferation gene discovery through functional genomics</article-title>
          <source>Science</source>
          <volume>319</volume>
          <year>2008</year>
          <fpage>620</fpage>
          <lpage>624</lpage>
          <pub-id pub-id-type="pmid">18239126</pub-id>
        </element-citation>
      </ref>
      <ref id="b0265">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Silva</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Profiling essential genes in human mammary cells by multiplex RNAi screening</article-title>
          <source>Science</source>
          <volume>319</volume>
          <year>2008</year>
          <fpage>617</fpage>
          <lpage>620</lpage>
          <pub-id pub-id-type="pmid">18239125</pub-id>
        </element-citation>
      </ref>
      <ref id="b0270">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luo</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Highly parallel identification of essential genes in cancer cells</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>105</volume>
          <year>2008</year>
          <fpage>20380</fpage>
          <lpage>20385</lpage>
          <pub-id pub-id-type="pmid">19091943</pub-id>
        </element-citation>
      </ref>
      <ref id="b0275">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scholl</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells</article-title>
          <source>Cell</source>
          <volume>137</volume>
          <year>2009</year>
          <fpage>821</fpage>
          <lpage>834</lpage>
          <pub-id pub-id-type="pmid">19490892</pub-id>
        </element-citation>
      </ref>
      <ref id="b0280">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barbie</surname>
              <given-names>D.A.</given-names>
            </name>
          </person-group>
          <article-title>Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1</article-title>
          <source>Nature</source>
          <volume>462</volume>
          <year>2009</year>
          <fpage>108</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="pmid">19847166</pub-id>
        </element-citation>
      </ref>
      <ref id="b0285">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mayo</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>C.Y.</given-names>
            </name>
            <name>
              <surname>Cogswell</surname>
              <given-names>P.C.</given-names>
            </name>
            <name>
              <surname>Rogers-Graham</surname>
              <given-names>K.S.</given-names>
            </name>
            <name>
              <surname>Lowe</surname>
              <given-names>S.W.</given-names>
            </name>
            <name>
              <surname>Der</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Baldwin</surname>
              <given-names>A.S.</given-names>
              <suffix>Jr.</suffix>
            </name>
          </person-group>
          <article-title>Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras</article-title>
          <source>Science</source>
          <volume>278</volume>
          <year>1997</year>
          <fpage>1812</fpage>
          <lpage>1815</lpage>
          <pub-id pub-id-type="pmid">9388187</pub-id>
        </element-citation>
      </ref>
      <ref id="b0290">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chien</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival</article-title>
          <source>Cell</source>
          <volume>127</volume>
          <year>2006</year>
          <fpage>157</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="pmid">17018283</pub-id>
        </element-citation>
      </ref>
      <ref id="b0295">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meylan</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Dooley</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Feldser</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Turk</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ouyang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Jacks</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma</article-title>
          <source>Nature</source>
          <volume>462</volume>
          <year>2009</year>
          <fpage>104</fpage>
          <lpage>107</lpage>
          <pub-id pub-id-type="pmid">19847165</pub-id>
        </element-citation>
      </ref>
      <ref id="b0300">
        <label>62</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luo</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Emanuele</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Creighton</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Schlabach</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Westbrook</surname>
              <given-names>T.F.</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>K.K.</given-names>
            </name>
            <name>
              <surname>Elledge</surname>
              <given-names>S.J.</given-names>
            </name>
          </person-group>
          <article-title>A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene</article-title>
          <source>Cell</source>
          <volume>137</volume>
          <year>2009</year>
          <fpage>835</fpage>
          <lpage>848</lpage>
          <pub-id pub-id-type="pmid">19490893</pub-id>
        </element-citation>
      </ref>
      <ref id="b0305">
        <label>63</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ngo</surname>
              <given-names>V.N.</given-names>
            </name>
            <name>
              <surname>Marani</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Staudt</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Downward</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells</article-title>
          <source>Oncogene</source>
          <volume>29</volume>
          <year>2010</year>
          <fpage>4658</fpage>
          <lpage>4670</lpage>
          <pub-id pub-id-type="pmid">20562906</pub-id>
        </element-citation>
      </ref>
      <ref id="b0310">
        <label>64</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carette</surname>
              <given-names>J.E.</given-names>
            </name>
          </person-group>
          <article-title>Haploid genetic screens in human cells identify host factors used by pathogens</article-title>
          <source>Science</source>
          <volume>326</volume>
          <year>2009</year>
          <fpage>1231</fpage>
          <lpage>1235</lpage>
          <pub-id pub-id-type="pmid">19965467</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack>
      <title>Acknowledgements</title>
      <p>I thank Thijn Brummelkamp, Louis Staudt, Helen Pickersgill and lab members for critical reading. Synthetic lethality research in the lab is supported by grants from the Austrian Science Fund (FWF) and Vienna Science and Technology Fund (WWTF).</p>
    </ack>
  </back>
  <floats-group>
    <fig id="f0005">
      <label>Fig. 1</label>
      <caption>
        <p>Schematic representation of synthetic lethality. Two genes are synthetic lethal only when their simultaneous inactivation results in cellular or organismal death. In this example, deletion of either gene A or gene B does not affect viability whereas inactivation of both at the same time is lethal.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="f0010">
      <label>Fig. 2</label>
      <caption>
        <p>Cartoon of a hypothetical synthetic interaction network. Genes are represented by blue, red and purple circles and their synthetic lethal interactors (buffering connections) indicated by red lines. Two processes (e.g., DNA repair and DNA replication) are buffered such that many single genes within each process are not essential (circles connected by red lines). Some genes are extrinsically buffered across two different processes whereas others are buffered by independent capacitator genes.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="f0015">
      <label>Fig. 3</label>
      <caption>
        <p>Forward screen approach to identify synthetic lethality. Cell lines (A–H) are grouped based on mutant status of a single gene (X). Essential genes that are common in the mutants but not in the wild type cell lines are potential synthetic lethal (SL) interactions with gene X and are selected for validation in an independent panel of cell lines.</p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <fig id="f0020">
      <label>Fig. 4</label>
      <caption>
        <p>Overview of a pooled shRNA screen set-up. Cell lines (A and B) are infected with short hairpin RNA libraries targeting thousands of gene products by RNAi. Cells are cultured to allow the depletion of those containing shRNAs that target essential genes. Genomic DNA is isolated and the vectors are quantified using so-called barcode sequences (short stretches of DNA) that are unique for each shRNA vector. By comparing the genes that are required in one cell line but not the other by custom micro-array or deep sequencing, potential synthetic interactions can be identified.</p>
      </caption>
      <graphic xlink:href="gr4"/>
    </fig>
    <fig id="f0025">
      <label>Fig. 5</label>
      <caption>
        <p>The synthetic lethality window. In both examples the mutant cells (purple lines) display a genetic interaction with a second gene that is progressively inhibited (<italic>x</italic>-axis). However, in the upper graph the synthetic lethality window is limited, as the wild type cells are also affected before viability is completely inhibited in the mutant cells (red line). In contrast, the lower graph shows that full inhibition of viability can be achieved in mutant cells without affecting the wild type cells.</p>
      </caption>
      <graphic xlink:href="gr5"/>
    </fig>
  </floats-group>
</article>